Health-Related Quality of Life Issues in Adolescents and Young Adults with Cancer: Discrepancies with the Perceptions of Health Care Professionals by Kaal, S.E.J. et al.






The following full text is a publisher's version.
 
 










Health-Related Quality of Life Issues in Adolescents and Young
Adults with Cancer: Discrepancies with the Perceptions of
Health Care Professionals
Suzanne E. J. Kaal 1,2, Emma K. Lidington 3 , Judith B. Prins 4, Rosemarie Jansen 1,2,†, Eveliene Manten-Horst 2 ,
Petra Servaes 4, Winette T. A. van der Graaf 2,5,6 and Olga Husson 2,5,7,8,*


Citation: Kaal, S.E.J.; Lidington, E.K.;
Prins, J.B.; Jansen, R.; Manten-Horst,
E.; Servaes, P.; van der Graaf, W.T.A.;
Husson, O. Health-Related Quality of
Life Issues in Adolescents and Young
Adults with Cancer: Discrepancies
with the Perceptions of Health Care





Received: 20 March 2021
Accepted: 19 April 2021
Published: 22 April 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Medical Oncology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands;
suzanne.kaal@radboudumc.nl
2 Dutch AYA ‘Young and Cancer’ Care Network, AYA IKNL, 3511 DT Utrecht, The Netherlands;
e.manten-ayanationaal@iknl.nl (E.M.-H.); w.vd.graaf@nki.nl (W.T.A.v.d.G.)
3 Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK; Emma.Lidington@rmh.nhs.uk
4 Department of Medical Psychology, Radboud University Medical Center, 6525 GA Nijmegen,
The Netherlands; judith.prins@radboudumc.nl (J.B.P.); petra.servaes@radboudumc.nl (P.S.)
5 Medical Oncology Department, Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital,
1066 CX Amsterdam, The Netherlands
6 Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center,
3015 GD Rotterdam, The Netherlands
7 Psychosocial Research and Epidemiology Department, Netherlands Cancer Institute—Antoni van
Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
8 Institute of Cancer Research, London SM2 5NG, UK
* Correspondence: o.husson@nki.nl
† deceased person.
Abstract: This study aimed to identify health-related quality of life (HRQoL) issues of relevance
for adolescent and young adult (AYA) cancer patients, the perception of relevant HRQoL issues for
AYA in generalby the health care professionals (HCP), and discrepancies between issues identified
by AYAs and HCP. Dutch AYAs aged 18–35 years at the time of cancer diagnosis (N = 83) and
HCPs (N = 34) involved in AYA oncology were invited to complete the Quality of Life for Cancer
Survivors questionnaire. HCPs rated physical symptoms such as fatigue, appetite, pain, constipation,
sleep disorders, nausea and neuropathy among AYA cancer patients significantly higher (i.e., more
problems) than AYA cancer patients. AYA cancer patients rated overall physical health and quality of
life, happiness, satisfaction, usefulness and support from others, all positively formulated questions,
significantly higher (i.e., more positive) than HCPs. The most highly rated issues (negative and
positive combined) for AYAs were: perceived support from others, distress about initial cancer
diagnosis, distress for family and overall quality of life. HCPs identified distress about diagnosis,
treatment, family and interference of illness with employment/study as the most problematic issues
(all negative) for AYAs. Five of the ten most common issues listed by patients and HCPs were the
same. Male AYAs, patients treated with curative intent and those with a partner rated positive HRQoL
issues higher than their counterparts. The discrepancy between the perception of patients and HCPs
illustrates the importance of patient involvement in organizing physical and psychosocial care.
Keywords: adolescent and young adult; AYA; cancer; health-related quality of life (HRQoL); health
care professionals’ perception
1. Introduction
Adolescents and young adults (AYA) diagnosed with cancer between the age of 18
and 35 are a distinct group compared to paediatric and adult oncology patients. Over the
last few decades, the incidence of cancer in AYAs has increased in Europe as well as in the
United States and Canada [1–3]. In the Netherlands, about 2700 new patients per year are
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diagnosed with cancer in this age group, which is 3% of all invasive cancer diagnoses [4].
While improvements in cancer survival in AYA patients lag behind those in children and
adults, about 80% of AYA cancer patients in the Netherlands will survive at least five
years [5].
These AYA survivors are in a phase of life where they normally reach developmental
milestones such as completing education, establishing intimate relationships, pursuing
gainful employment and having children [6]. Cancer poses a major challenge to achieving
these milestones. Problems concerning self-esteem, autonomy, body image, fertility and
sexuality may have a negative impact on health-related quality of life (HRQoL) in AYA
cancer patients [6–8]. Two recent review papers show that AYA with cancer experience
worse HRQoL compared to the general population [9,10]. Risk factors for poor HRQoL
in AYAs include low socio-economic status, tumour type (patients diagnosed with tumor
with poor prognosis report worse HRQoL), treatment status, female sex, unemployment,
high levels of distress and physical symptoms [11,12]. Measuring HRQoL in AYAs allows
physicians to better manage the complexity of caring for AYAs with cancer [10,13–15].
In recent years, there has been increasing interest in patient-reported outcomes (PROs),
including HRQoL, in AYA cancer patients [10]. A PRO is defined as information about
the status of a patient’s health condition that comes directly from the patient, without
interpretation of the patient’s response by a clinician or anyone else [16]. PROs are gener-
ally measured using structured questionnaires that evaluate a number of related domains
using scales comprised of multiple items which are validated in large populations and
psychometrically tested [17]. HRQoL includes multiple domains such as physical, psycho-
logical, social, and spiritual well-being [18,19]. While health researchers analyse and report
HRQoL in these domains as this is the level psychometrically validated, it can lead to loss
of information about the specific issues faced by patients [20,21]. Evaluating HRQoL on
item level provides detail about which issues result in high or low domain scores and can
help identify specific areas of need.
To achieve optimal patient-centred care, it is essential that health care professionals
(HCPs; medical and allied health care professionals) understand AYAs’ needs and prefer-
ences. A previous study in Australia showed that most oncology professionals recognized
the unique needs of AYAs (defined as 15–25 years old) with regard to biological, genetic,
epidemiological, psychological, social and cultural factors [22]. However, HCPs broadly
misconstrued the priorities of AYAs. HCPs believed AYAs would rank survival outcomes,
concerns about death and dying, and functional well-being as the most salient issues
following a cancer diagnosis. However, AYAs actually prioritised issues associated with
normal life stage development including peer and family relationships, engagement in
education and employment, development of autonomy and treatment environment (e.g.,
in- or outpatient, facilities and staff) [22]. This study showed significant discrepancies
between patient priorities and HCP perceptions in younger AYAs. However, it is unclear
if discrepancies exist in the older AYA cohort up to age 35. One could argue that this age
group has reached another life phase with different milestones, more responsibilities and
more independence from parents in comparison to AYAs aged 15–25 years [7] which may
be more or less aligned with the understanding of HCPs. In addition, it is important to
investigate whether this incongruence exists across health care systems, such as the Dutch
system, where there is a clear distinction between paediatric and adult oncology.
Identifying HRQoL priorities and providing care to meet these needs may lead to
higher patient satisfaction and can improve doctor-patient relationships and ultimately
overall quality of care [23]. Therefore, the aims of this exploratory study are to identify:
(1) the ten most common health-related quality of life (HRQoL) issues in adolescent and
young adult (AYA) cancer patients (according to sex, cancer type, treatment intention,
partner and family status); (2) the ten most common HRQoL issues of AYAs according
to the perceptions of health care professionals (HCP); (3) discrepancies between HRQoL
issues identified by AYAs and HCP.
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2. Materials and Methods
2.1. Participants
Patients were invited to participate if they were aged 18 to 35 years old at the time
of cancer diagnosis and had been seen by at least one member of the AYA team at the
Radboud university medical center (Radboudumc) in the Netherlands. The Radboudumc
is an expert center in delivering age-specific care for AYA cancer patients during and
after cancer treatment. The AYA team is a dedicated multidisciplinary team including a
medical oncologist, clinical nurse specialist, medical psychologist, social worker and clinical
occupational health physician. Patients receive standard medical care from their own
treating physician in the Radboudumc (e.g., medical oncologist, haematologist, etc.) and
visit the AYA team for age-specific questions and care needs. In general, patients attending
the AYA service have high disease severity, advanced disease, intensive treatments, and
high psychological needs. Eligibility for the study did not include treatment status (e.g., on
or off treatment), type of treatment (e.g., surgery, chemotherapy, etc.), or the number of
AYA team visits to reflect the heterogeneous population of AYA cancer patients visiting the
AYA team. Inclusion commenced January 2012 and ended March 2016.
HCPs were eligible to participate if they were involved in the care of AYA cancer
patients in the Netherlands. HCPs were invited to participate in person at the 2017 annual
AYA congress on age-specific care. In addition, HCP affiliated with the Dutch AYA ‘Young
and Cancer’ Care Network (www.ayazorgnetwerk.nl (accessed on 20 March 2021)) were
invited to participate via email.
2.2. Procedure
Potential patient participants were recruited by postal invitation. Patients willing
to participate responded to a member of the AYA team by email and provided informed
consent. The AYA team member provided a link to all participants by e-mail to complete
the questionnaire online. No reminders were sent. The research ethics committee deter-
mined the study did not require full review and approval (CMO Regio Arnhem-Nijmegen,
#2016-2872).
2.3. Measures
2.3.1. Sociodemographic and Clinical Characteristics
Demographic data, including age, sex, partnership, number of children, living situ-
ation, educational attainment and employment status were self-reported by the patient.
Medical data, including tumour type, disease stage, treatments, treatment status at partici-
pation (on/off treatment), treatment intent, and time since initial diagnosis were extracted
from medical records by one of the researchers (SK).
HCPs also self-reported background information including age, gender, profession,
hospital and the number of AYA cancer patients seen per month.
2.3.2. Health-Related Quality of Life
AYA Cancer Patients
Patient participants completed the modified version of the Quality of Life for Cancer
Survivors (QoL-CS) questionnaire [24] which originally consists of 41 items measuring
the negative and positive impact of cancer in four domains: physical, mental, social and
spiritual. Respondents answer each item on an interval rating scale ranging from 0 to 10.
We adapted the questionnaire by adding four items regarding neuropathy (a burning or
tingling sensation or a feeling of numbness), concerns about dying, concerns about fertility
and concerns that family members will get cancer. These were added to reflect issues that
were faced in daily clinical practice and frequently reported in our multidisciplinary AYA
team meetings. The items regarding fear of recurrence and spreading (metastases) were
combined into 1 item to make the question applicable for everyone to answer. Therefore,
the total number of items is 44. Questions focus on negative impacts, with higher scores
representing worse scores, or positive impacts, with higher scores representing better
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scores. An example of a negative question in the physical domain: ‘To what extent are
sleep changes a problem for you?’ (0 = no problem, 10 = severe problem). An example of a
positive impact question: ‘How useful do you feel?’ (0 = not at all, 10 = extremely). Three
items (importance of religious activities, importance of spiritual activities and spiritual
change) were excluded from our analyses, as they reflect religious aspects and their intrinsic
value differs per person dependent on cultural and religious background.
HCPs were asked to complete the modified QoL-CS questionnaire according to the
extent they believed AYA patients experienced each issue.
3. Statistical Analysis
Analyses were performed using SPSS statistical software (version 24, Chicago, IL,
USA) and two-sided p values of <0.05 were considered statistically significant. Differ-
ences in HRQoL items between two groups were compared with an independent t-test
and between more than two groups with an analysis of variance (ANOVA). For AYA
cancer patients, HRQoL items were analysed according to five variables: age (emerging
adult (18–25 years)/young adult (26–35 years at diagnosis), gender (male/female), cancer
type (testicular, sarcoma, breast, hematologic, gynaecologic and other), treatment intent
(curative/palliative), disease phase (undergoing active treatment/completed treatment),
partner (yes/no) and children (yes/no). Clinical significance was determined by applying
Normans rule of thumb (observed difference exceeds half mean standard deviation) [25].
4. Results
4.1. Patient Sociodemographic and Clinical Characteristics
A total of 89 AYAs completed the online questionnaire. This amounted to 57% of
those who responded to the letter invitation (155 patients) and 29% of the total AYAs
invited (309 patients). A small proportion of patients did not participate due to technical
problems. Six patients were excluded due to ineligibility based on age: four were younger
than 18 years when diagnosed with cancer and two were older than 35 years at the
time of diagnosis. Table 1 displays the sociodemographic, disease, and treatment-related
characteristics of the final sample (83 patients). The mean age at the time of diagnosis was
27.5 (SD = 4.6) years. The average time since diagnosis was 2.1 years (SD = 2.6), 71 (86%)
patients received curative treatment and 43 (52%) were male. The common diagnoses were
testicular cancer (34%) and sarcoma (19%).
Table 1. Demographic and clinical data of AYA cancer patients.




Age at diagnosis, mean 27.5 (4.6)
Age at diagnosis
Emerging adult (18–25 years) 30 (36%)
Young adult (26–35 years) 53 (64%)
Age at survey 29.6 (4.8)
Time since cancer diagnosis 2.1 (2.6)
Cancer Diagnosis
Testicular cancer 28 (34%)
Sarcoma 16 (19%)
Breast cancer 10 (12%)
Lymphoma/leukaemia 10 (12%)
Gynaecological cancer 9 (11%)
Melanoma 3 (4%)
Other * 7 (8%)
J. Clin. Med. 2021, 10, 1833 5 of 15
Table 1. Cont.
AYA Cancer Patients N = 83
Stage
NA 9 (11%)
Stage 1 11 (13%)
Stage 2 25 (30%)
Stage 3 13 (16%)












Immunotherapy/targeted therapy 13 (16%)
Hormonal therapy 7 (8%)








With parents 14 (17%)
On own 24 (29%)
With partner 44 (53%)
Highest Completed Education
Low/intermediate vocational education or less 38 (46%)




Not all numbers add up to 83 because of missing data * Other cancer types comprise brain tumour (n = 1), sigmoid
carcinoma (n = 1), oropharyngeal cancer (n = 1), neuroendocrine tumour (n = 1), salivary gland cancer (n = 1),
adrenal carcinoma (n = 1), lung cancer (n = 1).
4.2. Health Care Professionals Characteristics
Thirty-four HCPs from 12 hospitals completed the QoL-CS questionnaire. Respon-
dents included 11 medical oncologists, 11 nurses, five nurse specialists, two psychologists,
one social worker, one physical therapist, one rehabilitation specialist, and one who did not
report his/her medical profession. The mean age of the HCPs was 45 years (range 23–64
years) and four (12%) were male. The HCPs saw an average of 15 (range 1–70) AYA cancer
patients per month. Four HCPs were from non-university hospitals.
4.3. HRQoL Items
Table 2 shows the mean score on each HRQoL item rated by AYA cancer patients
and HCPs. HCPs rated physical symptoms like fatigue (7.3 vs. 2.7; p < 0.001), appetite
(5.1 vs. 1.5; p < 0.001), pain (4.3 vs. 2.3; p < 0.001), constipation (3.7 vs. 1.8; p < 0.001), sleep
disorders (5.2 vs. 2.8; p < 0.001), nausea (4.8 vs. 1.6; p < 0.001) and neuropathy (4.8 vs.
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2.2; p < 0.001) among AYA cancer patients significantly higher than AYA cancer patients.
The differences for each of these items were clinically relevant. AYA cancer patients rated
overall physical health (6.6 vs. 5.7; p = 0.004) and quality of life (7.2 vs. 6.2; p = 0.003),
happiness (7.1 vs. 6.2; p = 0.012), satisfaction (6.8 vs. 5.9; p = 0.012), usefulness (6.4 vs.
5.3; p = 0.014) and support from others (8.1 vs. 6.2; p < 0.001), all positively formulated
questions, significantly higher than HCPs. HCPs rated distress about time since treatment
completion (6.9 vs. 5.5; p = 0.014), anxiety (6.5 vs. 3.7; p < 0.001), depression (5.0 vs. 3.0;
p < 0.001), fear of future tests (6.9 vs. 4.7; p < 0.001), fear of recurrent cancer (7.1 vs. 5.4;
p = 0.001), fear of dying (6.2 vs. 4.1; p = 0.001), problems with personal relationships (6.6
vs. 3.7; p < 0.001), sexuality (7.2 vs. 4.3; p < 0.001), concerns about fertility (7.3 vs. 5.0;
p = 0.001), interference with illness of employment/study (7.8 vs. 6.2; p = 0.004), feeling
isolated (6.1 vs. 3.7; p < 0.001), uncertainty about the future (6.6 vs. 5.2; p = 0.010) and life
purpose (6.1 vs. 4.5; p = 0.005) as clinically and statistically significantly more problematic
HRQoL items than AYAs.
Table 2. Mean scores (SD) on HRQoL items of AYA cancer patients and health care professionals (scale range 0–10).
AYA (n = 83)
Mean
(Standard Deviation)





Fatigue 4.4 (2.7) 7.3 (1.2) 0.000 **a
Appetite 1.5 (2.2) 5.1 (2.3) 0.000 **a
Pain 2.3 (2.3) 4.3 (2.0) 0.000 **a
Constipation 1.8 (2.4) 3.7 (1.8) 0.000 **a
Sleep 2.8 (2.8) 5.2 (1.9) 0.000 **a
Nausea 1.6 (2.6) 4.8 (2.3) 0.000 **a
Menstrual changes 3.7 (3.8) 5.2 (2.5) 0.074
Neuropathy 2.2 (2.5) 4.8 (2.6) 0.000 **a
Overall physical health b 6.6 (1.6) 5.7 (1.4) 0.004 **a
Psychological Well-Being
Coping difficulties 4.1 (2.6) 6.2 (1.5) 0.000 **a
Quality of life b 7.2 (1.7) 6.2 (1.1) 0.003 **a
Happiness b 7.1 (1.9) 6.2 (1.3) 0.012 *a
Control b 5.5 (2.6) 5.1 (1.6) 0.411
Satisfaction b 6.8 (1.9) 5.9 (1.3) 0.012 *a
Concentration/memory b 5.7 (2.2) 5.0 (1.6) 0.095
Usefulness b 6.4 (2.3) 5.3 (1.6) 0.014 *
Appearance 5.0 (3.0) 6.2 (2.0) 0.030 *
Self-concept 3.8 (2.8) 6.4 (1.7) 0.000
Distress about initial diagnosis 7.6 (2.5) 8.5 (1.5) 0.054
Cancer treatment distress 6.9 (2.3) 7.8 (1.5) 0.047 *
Distress about time since treatment completion 5.5 (2.8) 6.9 (1.4) 0.014 *a
Anxiety 3.7 (2.7) 6.5 (1.3) 0.000 **a
Depression 3.0 (2.6) 5.0 (1.3) 0.000 **a
Fear of future tests 4.7 (2.7) 6.9 (1.4) 0.000 **a
Fear of second cancer 4.8 (2.9) 5.7 (2.1) 0.107
Fear recurrent cancer 5.4 (2.5) 7.1 (1.2) 0.001 **a
Fear of dying 4.1 (3.2) 6.2 (1.8) 0.001 **a
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Table 2. Cont.
AYA (n = 83)
Mean
(Standard Deviation)





Family distress 7.6 (2.0) 7.8 (1.1) 0.671
Support from others b 8.1 (1.8) 6.2 (1.6) 0.000 **a
Personal relationships 3.7 (2.9) 6.6 (1.6) 0.000 **a
Sexuality 4.3 (3.3) 7.2 (1.2) 0.000 **a
Concerns about fertility 5.0 (3.6) 7.3 (1.8) 0.001 **a
Interference of illness with employment or study 6.2 (3.0) 7.8 (1.2) 0.004 **a
Home activities 6.5 (2.7) 7.2 (1.2) 0.105
Feel isolated 3.7 (3.0) 6.1 (1.5) 0.000 **a
Financial burden 6.3 (3.0) 5.9 (1.6) 0.533
Concerns that family members will get cancer 3.9 (2.8) 4.8 (1.7) 0.097
Spiritual Well-Being
Importance of religious activities c 2.1 (3.3) 3.6 (1.9) 0.020 *a
Importance of spiritual activities c 1.3 (2.2) 4.4 (2.0) 0.000 **a
Spiritual change c 1.8 (2.4) 4.9 (1.8) 0.000 **a
Uncertainty future 5.2 (2.9) 6.6 (1.6) 0.010 *a
Illness positively changed life b 5.1 (2.8) 6.2 (1.6) 0.028 *
Life purpose b 4.5 (3.1) 6.1 (1.6) 0.005 **a
Hopefulness b 6.8 (2.2) 7.3 (1.2) 0.169
* p < 0.05; ** p < 0.01; a = clinical relevant; b = Positively formulated item; All other items are negatively formulated: the higher the score,
the bigger the problem; c = neutral formulated items because of religious background, not in analysis.
Table 3a shows the top ten most highly rated HRQoL issues by AYA cancer patients
and HCPs and the overlapping items in the middle column. Support from others appeared
as the most highly scores HRQoL item among AYA cancer patients, followed by distress
about initial cancer diagnosis and distress for family. These last two items were scored as
most important by HCP. Only five out of ten items were similar for patients and HCP. Six
out of ten items of AYA cancer patients were positively formulated. Table 3b displays top
ten most highly rated HRQoL items by AYA cancer patients and HCP for only negatively
formulated items. It shows that the first three items are similar for both groups (distress
about cancer diagnosis, distress for family and distress about cancer treatment). Six out of
ten items overlapped.
Table 4a–c depict the top ten most commonly experienced HRQoL items for AYA
cancer patients according to gender, cancer type, treatment intention, partner, having
children, disease phase and age group. It shows that male AYA cancer patients scored
significantly higher on items concerning quality of life (p = 0.019), happiness (p = 0.004),
satisfaction (p = 0.025), hopefulness (p = 0.009), overall physical health (p = 0.002) and
experienced less interference with activities at home (p = 0.022). Between tumour types
there were differences on the items: quality of life (p = 0.023), happiness (p = 0.012), cancer
treatment distress (p = 0.027), overall physical health (p = 0.004) and interference with
activities at home (p = 0.020). For sarcoma patients these effects were larger than for
patients with other cancer types. AYA cancer patients treated with curative intention scored
significantly higher on items concerning quality of life (p = 0.006), hopefulness (p = 0.000)
and overall physical health (p = 0.000) in comparison with patients treated with palliative
intent. AYA patients with a partner scored significantly higher on happiness (p = 0.008),
satisfaction (p = 0.013) and overall physical health (p = 0.049). The difference in overall
physical health between groups was not clinically relevant. There were no differences in
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top ten most experienced items when stratified for having children or not, disease phase
(active vs. completed treatment) and age group (emerging adults vs. young adults).
Table 3. (a) Top 10 most important HRQoL issues among AYA cancer patients and health care professionals including posi-
tive formulated items. (b) Top 10 most important HRQoL issues among AYA cancer patients and health care professionals
excluding positive formulated items.
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Table 4. (a) Most important HRQoL items (mean (SD)) among AYA cancer patients (n = 83) for gender and cancer type. (b) Most important HRQoL items (mean (SD)) among AYA cancer
patients (n = 83) for treatment intention, partner and children. (c) Most important HRQoL items (mean (SD)) among AYA cancer patients (n = 83) for disease phase and age.
(a)
Gender Cancer Type
Male Female p-Value Testicular Sarcoma Breast Hematologic Gynaecologic Other p-Value
Support from Others 8.4 (1.6) 7.8 (1.9) 0.082 8.6 (1.6) 8.1 (1.7) 7.2 (1.9) 8.1 (2.7) 7.5 (1.3) 8.1 (1.5) 0.351
Distress Initial Cancer Diagnosis 7.4 (2.3) 7.7 (2.6) 0.635 7.5 (2.2) 6.9 (2.6) 7.7 (3.3) 6.1 (3.0) 8.1 (1.7) 8.7 (1.9) 0.148
Distress for Family 7.7 (1.9) 7.5 (2.1) 0.62 7.5 (1.8) 8.4 (1.5) 7.0 (2.9) 6.7 (2.5) 7.3 (2.0) 8.5 (1.3) 0.153
Quality of Life 7.6 (1.5) 6.7 (1.8) 0.019 *a 8.0 (1.4) 6.8 (1.8) 7.2 (1.0) 7.2 (1.2) 6.3 (2.3) 6.4 (2.1) 0.023 * b,c,d,e,f,g,
Happiness 7.6 (1.6) 6.5 (2.0) 0.004 **a 7.8 (1.8) 7.2 (1.4) 7.4 (1.4) 7.3 (1.3) 5.9 (2.2) 5.9 (2.2) 0.012 * c,d,e,f,g,h,i,j
Cancer Treatment Distress 6.7 (2.0) 7.1 (2.6) 0.428 6.6 (2.0) 7.5 (2.1) 5.9 (3.3) 5.6 (2.6) 8.3 (1.2) 7.9 (1.8) 0.027 * c,d,f,g,i,j,k,l
Satisfaction 7.3 (1.8) 6.4 (2.0) 0.025 * 7.5 (1.9) 6.5 (2.0) 6.9 (1.4) 7.4 (1.6) 6.0 (2.3) 6.1 (2.0) 0.14
Hopefulness 7.4 (1.9) 6.1 (2.4) 0.009 **a 7.7 (1.6) 5.9 (2.6) 7.2 (1.5) 6.5 (2.0) 5.9 (2.7) 6.1 (2.6) 0.063
Overall Physical Health 7.1 (1.4) 6.0 (1.6) 0.002 **a 7.5 (1.3) 5.9 (1.2) 6.6 (1.2) 6.5 (1.4) 6.1 (1.7) 5.8 (1.8) 0.004 ** b,c,d,i,m,n
Interference Activities at Home 5.8 (2.8) 7.2 (2.5) 0.022 *a 5.1 (2.7) 8.2 (1.7) 6.9 (1.7) 6.3 (3.1) 6.5 (3.2) 7.4 (2.4) 0.020 * b,c,d,e,k,l,m
(b)
Treatment Intention Partner Children
Curative Palliative p-Value Yes No p-Value Yes No p-Value
Support from Others 8.1 (1.8) 8.3 (1.1) 0.745 8.4 (1.5) 7.6 (1.6) 0.038 7.8 (1.8) 8.4 (1.4) 0.102
Distress Initial Cancer Diagnosis 7.4 (2.6) 8.8 (1.3) 0.071 7.9 (2.3) 7.1 (2.4) 0.166 8.2 (2.1) 7.4 (2.4) 0.122
Distress for Family 7.5 (2.1) 8.6 (1.3) 0.076 7.7 (2.0) 7.5 (2.0) 0.764 7.7 (1.7) 7.6 (2.2) 0.858
Quality of Life 7.4 (1.5) 6.2 (2.4) 0.006 **a 7.4 (1.6) 6.6 (1.9) 0.073 7.3 (1.7) 7.1 (1.8) 0.715
Happiness 7.2 (1.8) 6.2 (2.4) 0.079 7.4 (1.8) 6.2 (2.0) 0.008 **a 7.3 (1.7) 7.0 (2.0) 0.541
Cancer Treatment Distress 6.8 (2.4) 7.7 (1.2) 0.224 7.1 (2.3) 6.8 (2.1) 0.61 7.0 (2.4) 7.0 (2.2) 0.972
Satisfaction 7.0 (1.9) 6.2 (2.4) 0.195 7.2 (1.7) 6.0 (2.2) 0.013 *a 7.2 (1.7) 6.6 (2.0) 0.204
Hopefulness 7.1 (1.9) 4.6 (2.6) 0.000 **a 7.0 (2.1) 6.5 (2.3) 0.32 6.7 (2.3) 6.9 (2.1) 0.715
Overall Physical Health 6.9 (1.3) 4.8 (1.9) 0.000 **a 6.8 (1.4) 6.0 (2.0) 0.049 * 6.7 (1.5) 6.5 (1.6) 0.603
Interference Activities at Home 6.4 (2.8) 7.0 (2.5) 0.448 6.4 (2.8) 6.5 (2.5) 0.856 6.3 (2.6) 6.5 (2.8) 0.784









Adults Young Adults p-Value
Support from Others 8.0 (1.7) 8.1 (1.8) 0.77 8.3 (2.0) 8.0 (1.6) 0.43
Distress Initial Cancer Diagnosis 7.6 (2.7) 7.5 (2.4) 0.88 6.9 (2.5) 7.9 (2.4) 0.06
Distress for Family 7.2 (2.8) 7.8 (1.6) 0.26 7.7 (1.8) 7.6 (2.1) 0.83
Quality of Life 6.6 (1.9) 7.4 (1.6) 0.05 7.5 (1.5) 7.0 (1.8) 0.22
Happiness 6.7 (1.8) 7.2 (1.9) 0.34 7.4 (1.7) 6.9 (2.0) 0.27
Cancer Treatment Distress 6.5 (2.7) 7.1 (2.2) 0.33 6.9 (2.5) 6.9 (2.2) 0.89
Satisfaction 6.6 (2.0) 6.9 (1.9) 0.48 7.2 (1.8) 6.7 (2.0) 0.27
Hopefulness 6.4 (2.0) 6.9 (2.3) 0.32 7.1 (2.1) 6.6 (2.3) 0.36
Overall Physical Health 6.3 (1.5) 6.7 (1.6) 0.29 6.8 (1.4) 6.4 (1.6) 0.34
Interference Activities at Home 6.3 (2.1) 6.5 (2.9) 0.8 6.6 (2.9) 6.3 (2.6) 0.64
(a) HRQoL: health-related quality of life; SD: standard deviation; * p < 0.05; ** p < 0.01; a = clinically relevant; b = testicular vs. sarcoma; c = testicular vs. gynaecologic; d = testicular vs. other; e = gynaecologic vs.
sarcoma; f = gynaecologic vs. breast; g = gynaecologic vs. hematologic; h = sarcoma vs. other; i = breast vs. other; j = hematologic vs. other; k = sarcoma vs. breast; l = sarcoma vs. hematologic; m = testicular vs.
breast; n = testicular vs. hematologic. (b) HRQoL: health-related quality of life; SD: standard deviation; * p < 0.05; ** p < 0.01; a = clinically relevant; (c) HRQoL: health-related quality of life; SD: standard deviation.
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5. Discussion
The results of the current study indicate that there is a considerable discrepancy in the
level of impact cancer and its treatment have on HRQoL in AYA cancer patients and the
level perceived by HCPs. AYA cancer patients rated most HRQoL items as less problematic
than HCPs, indicating that professionals believe that the burden of cancer and treatment is
larger than it is actually perceived by patients themselves. This holds for all four domains
(physical, psychological, social and spiritual) of the QoL-CS questionnaire. Top ten items
for AYA cancer patients are dominated by six positively formulated questions, indicating
that AYA cancer patients are more inclined to emphasize HRQoL items with a positive
connotation like happiness, satisfaction, hopefulness and social support. In our study,
stratified analyses showed that male patients, patients being treated with curative intent
and patients who have a partner valued positive formulated HRQoL items higher.
Our results are in line with previous studies. Thompson et al. found that there
is a significant gap between the identified health care preferences of AYA with cancer
(15–25 years) and the understanding of the Australian oncology HCP who deliver their
care. HCP significantly underestimated the breadth of psychosocial concerns in AYA with
cancer and believed they focused on survival and physical wellbeing [22]. In contrast, a
study among older patients (mean age 55 years) found there was considerable consistency
between physicians’ and patients’ perceptions of the needs and support that the patients
received [23]. There was, however, a discrepancy between the actual and desired level of
emotional and cognitive support. Another study found that the issues older cancer patients
(mean age 61.5 years) preferred to be addressed, were the issues that HCP felt difficult to
deal with [26].
A study among 294 long-term breast cancer survivors almost 6 years after cancer
diagnosis (mean age 50.9 years) using the QoL-CS questionnaire showed that survivors
experienced a negative impact on overall quality of life but also benefits including hopeful-
ness, having a life purpose and having a positive change after treatment, which helped
to cope with poorer outcomes [27]. However, in our study HCP scored life purpose and
positive change higher than AYA. In our study we also observed many of these positive
effects, therefore it could be hypothesized that resilience and post-traumatic growth can be
important consequences in the AYA population after cancer treatment [28,29].
Male AYA cancer patients scored higher on items concerning quality of life, happiness,
hopefulness, overall physical health and experienced less interference with activities at
home to a clinically relevant level. This is in line with a previous study where male gender
showed a positive correlation with empowerment, which may be related to the use of
different coping strategies [30]. It could also be due to the fact that a substantial part of
our study sample includes male patients with testicular cancer (34%) who, in general, have
a good prognosis and a relatively short treatment duration. AYA patients with partners
scored higher on happiness and satisfaction to a clinically relevant level, which illustrates
the buffering and stabilizing effect of the social support of a partner [31]. Interestingly, no
differences were found for disease phase (active v. completed treatment) and age group
(emerging adult vs. young adult). It could be that these differences are not expressed in
the top 10 HRQoL items, but in the other items that we have not been examined in detail.
This is supported by the findings of a recent study were no significant differences in any
HRQoL domain by cancer type, and few significant differences were observed in PROMIS
domains between developmental groups among on-treatment AYA survivors. In contrast,
off-treatment emerging adults and young adults reported significantly higher symptoms
and worse functioning compared to adolescents [32].
It is valuable to identify the HRQoL areas where AYA cancer patients experience the
most problems. The discrepancy between the level HRQoL problems reported between
AYAs and HCPs illustrates that we must invest in clarifying patient needs and in training
to deliver age-specific psychosocial care for oncology HCPs. The results of this study will
add to the growing body of work in the needs of AYA oncology patients and support the
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tailoring of AYA-specific care. It also emphasizes the importance of patient experiences
and needs in the development of age-specific health care services [33].
Since 2013, the Dutch AYA ‘Young and Cancer’ Care Network has been established
through co-creation with AYA cancer patients and HCPs from university medical centres
and large regional centres. The main goal of this AYA Care Network is to improve the care
for and the quality of life of AYA cancer patients by developing structural, standardized,
comprehensive and patient-centred guidelines for AYA cancer care, research and education.
An e-module has been developed recently to educate students and health care professionals
in the Netherlands on age-specific topics relevant to AYA cancer patients. Better training
of HCPs can reduce discrepancies in perceptions of AYA supportive care needs between
patients and HCPs.
We acknowledge several limitations of our study. First, AYA cancer patients responded
based on their individual experience, while HCPs evaluated the HRQoL of the AYA cancer
patient population in general not referring to a specific time after diagnosis, disease or
treatment stage. HCPs may have responded based on patients currently undergoing
treatment, while most of the patients were around two years from diagnosis. Furthermore,
the HCP sample was composed primarily with professionals from the medical oncology
discipline, with limited inclusion of allied health professionals including psychosocial
providers. Both, may also have skewed the focus on symptoms among the HCPs and
may under-represent more psychosocial aspects of an AYAs’ HRQoL. Second, AYA cancer
patients were treated in a single centre and received multidisciplinary care by a dedicated
AYA team, while the HCPs were from several centres. It could be that HRQoL item scores
are better than those of AYA cancer patients treated in other centres in the Netherlands
without age-specific care. The patients in the current study sample were diagnosed with
a relatively advanced stage of disease and were treated intensively, mostly with more
than one treatment modality. This is an overestimation in disease severity of the entire
AYA cancer population [34]. Both factors limit the generalizability of the results of the
current study.
Third, the QoL-CS questionnaire is not an AYA-specific HRQoL questionnaire. It
was validated in a sample of cancer survivors with a mean age of 49.6 years who were
on average 6.7 years after cancer diagnosis [24]. Therefore, we assume that the QoL-CS
questionnaire has less discriminative value in our AYA population as our sample was a
median of 2.1 years after cancer diagnosis. An AYA-specific HRQoL questionnaire was
not in place when we started with this research. In the meantime, a few AYA specific
questionnaires have been developed. For example, adult and paediatric measures have
been adapted to the specific issues relevant to AYAs and have AYA versions (PedsQL) [35]
and there are measures which have been developed with and designed specifically for AYAs
(CNQ-YP) [36]. In response to the need for AYA specific questionnaires the EORTC Quality
of Life Group are also developing the EORTC-QLQ-AYA module with AYA specific issues
(e.g., impact on family, dependency on others, interrupted education, workability) [37].
The first phase of the questionnaire development showed that AYAs with cancer have to
deal with disrupted life plans and difficulty establishing romantic relationships which
are likely to be more common to AYAs with cancer and might not be captured by the
tool used in this study [37]. The Impact Of Cancer AYA (IOC-AYA) questionnaire has
shown good psychometric properties to measure positive and negative HRQoL aspects
in the AYA population [14] and could, therefore, also be an asset in future research using
AYA-specific questionnaires. Moreover, studies have shown that the meaning of patients’
self-evaluations of their quality of life may not be the same across different points in time, a
phenomenon known as response shift. It reflects change that occurs because of adaptation
to cancer, not true change due to cancer progression [38]. This phenomenon could have
influenced our results.
A fourth limitation is the low response rate and potential sampling bias, which is not
unusual in studies in young patients with cancer. Our study, however, had an even lower
response than previous questionnaire studies among AYAs (29% response rate in the current
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study sample versus 43% and 52% in previous studies) [39,40]. Unfortunately, we do not
have information regarding the reasons for not participating. As demographic and clinical
data were not collected from the non-responders, we could not rule out selection bias. The
results of our exploratory study should be interpreted with caution, the low number of
participants limited us to perform multivariate analyses and apply Bonferroni corrections.
A fifth limitation is that we have used the QoL-CS questionnaire in a group of oncology
HCPs. As the QoL-CS questionnaire was validated in cancer survivors [24], one could
question whether the HCPs interpreted the questions in a similar way. Additionally, HCPs
may not have been able to estimate the effect on HRQoL for AYAs across cancer types as
they may only have treated a few patients with specific types of cancer. Sixth, the QoL-CS is
a cancer-generic HRQoL questionnaire. We might have missed some AYA-specific and/or
disease-specific HRQoL issues. There is an ongoing debate in the literature on the optimal
HRQoL measurement strategy for AYAs given their heterogeneity in terms of cancer types
and developmental stages [41,42]. A core item set combined with the advantages of a
flexible measurement system will support future collaborative and comparative research
efforts to improve AYA health outcomes.
Seventh, the HCP sample was relatively small and only included a few physicians.
As most of the data were gathered at an AYA conference, one could assume that HCPs in
the sample were highly dedicated and informed in the care of AYA cancer patients, which
could skew the data.
In conclusion, this exploratory study showed incongruence between the views of AYA
cancer patients and HCPs regarding the most problematic HRQoL items. Overall, HCPs
in this study believed that the burden of cancer and its treatment is bigger than actually
perceived by the patients themselves. Assessing HRQoL can, therefore, be of clinical
importance in order to provide optimal age-specific care. The discrepancy between patients
and HCP illustrates the importance of co-creation of physical and psychosocial survivorship
care for this age group. Future research should use an age-specific questionnaire, which
discriminates between positive and negative HRQoL items and its impact on overall
HRQoL in AYA cancer patients.
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